This medical technology startup provides surgeons with rapid and precise diagnostic tools for real-time margin analysis during procedures. Their technology aims to reduce uncertainty for patients by enabling surgeons to improve the accuracy of their operations.
Funding
Funding not disclosed
Founders
Product
Problem
In cancer surgery, even microscopic remnants of tissue left behind can lead to future relapse. Current methods for margin analysis can be time-consuming, lengthy intraoperative pathological exams, or lack the precision needed for complete tumor removal. This uncertainty can cause patient anxiety and necessitate subsequent surgeries or treatments.
Solution
CELEOS offers a solution for real-time surgical margin definition using the SpiderMass system. This system allows for contactless, in-situ sampling via laser ablation, followed by molecular analysis using mass spectrometry. An AI framework provides tissue characterization, giving surgeons immediate and accurate insights into tissue composition. The goal is to reduce the chance of positive margins, decrease cancer relapses, and improve patient outcomes by ensuring complete tumor removal during the initial surgery.
Target Audience
The primary target audience includes oncological surgeons seeking real-time, precise diagnostic tools for margin analysis during cancer surgeries, as well as veterinarians and clinicians in dermatology and cosmetology.
Features
- Contactless in-situ sampling using a fibered laser for microscopic tissue extraction
- Molecular analysis via mass spectrometry for detailed tissue characterization
- Real-time AI framework for interpretable tissue sorting and margin definition
- Capability to measure molecular characteristics of tissue with high sensitivity and specificity
- Integration of machine learning techniques for tissue classification
- Potential applications in human surgeries, animal health, dermatology, and cosmetology